Tel Aviv- and SF-based Edelbyte, which is building a data analytics platform optimized for AI agents, emerges from stealth with $70M across Series A and seed (Tim Keary/Forbes)
Edelbyte officially launched out of stealth backed by $70 million secured through seed and Series A financing rounds. The dual-headquartered company operates out of both Tel Aviv and San Francisco to build a data analytics platform optimized for AI agents. While the substantial capital marks a notable debut, specific investor identities and the formal product rollout schedule remain undisclosed.
Key points
Substantial launch capital positions the company to aggressively develop its targeted dat…: Substantial launch capital positions the company to aggressively develop its targeted data analytics infrastructure.
The business maintains a strategic operational footprint across both the United States an…: The business maintains a strategic operational footprint across both the United States and Israeli technology hubs.
Specific participating investment firms and official product release dates have not yet b…: Specific participating investment firms and official product release dates have not yet been made public.
Sources checked by our analysis pipeline: 1
Desmond Shum: |
April Roach / CNBC: |
New York Times: |
New York Times: |
New York Times: |
Owen Walker / Financial Times: |
Vlad Savov / Bloomberg: |
Bailey Lipschultz / Bloomberg: |
@firesidealpha: |
Luke Plunkett / Aftermath: |
Eduardo Baptista / Reuters: |
Bloomberg: |
Marcus Mendes / 9to5Mac: |
Richard Adams / The Guardian: |
Berber Jin / Wall Street Journal: |
Elizabeth Chamberlain / iFixit News: |
Jake Roach / Tom's Hardware: |
Lenny Rachitsky / Lenny's Newsletter: |
Declan Harty / Politico: |
Jordan Novet / CNBC: |
Dan Goodin / Ars Technica: |
Politico: |
Jessica Elgot / The Guardian: |
Andrew Silver / Reuters: |
Lawrence Abrams / BleepingComputer: |
Gian Volpicelli / Bloomberg: |
Reuters: |
Wall Street Journal: |
Loreben Tuquero / Poynter: |
This is a Techmeme archive page. It shows how the site appeared at 10:21 AM ET, November 11, 2026.
The most current version of the site as always is available at our home page. To view an earlier snapshot click here and then modify…
Healthcare technology developers are increasingly pushing to ingest extensive patient records and administrative files to power broader clinical recommendations. This rapid transition from narrow, single-purpose functions to wide-ranging medical decision support challenges traditional clinical perspectives on data limitation. The shift marks an aggressive effort by digital health platforms to expand their operational footprints across patient care.
To accelerate therapeutic development, Anthropic has forged partnerships with pharmaceutical companies and biotechs like Bristol Myers Squibb and BigHat Biosciences. The initiatives leverage the company's Claude AI models to engineer treatments for rare diseases, food allergies, and various forms of cancer. While laboratory tests show promise in optimizing drug molecules, the technologies remain strictly in preclinical development phases.
The system was developed using training data from more than 100 million cell profiles spanning 68 different tissues. It aims to support scientific efforts to understand how variations in genetic code impact biological functions across various tissue types.